Literature DB >> 6455503

Studies of hypothalamic function in Huntington's chorea.

P J Lavin, I Bone, P Sheridan.   

Abstract

In eight patients with classical Huntington's chorea hypothalamic function was assessed by the insulin tolerance test, the thyrotrophin releasing hormone test, the gonadotrophin releasing hormone test and water deprivation and the results compared with those of 10 control subjects. All patients ceased to have choreiform movements for approximately 60 minutes during the insulin tolerance test. Four of the patients failed to show clinical features of stress in response to hypoglycaemia. The fasting blood glucose level and blood glucose response to insulin were similar for the two groups. However, the response of plasma cortisol (p less than 0.05) and of growth hormone (p less than 0.05) to hypoglycaemia was earlier in patients than controls, though peak responses were the same for each group. The thyrotrophin releasing hormone test revealed no difference in basal levels of thyroid stimulating hormone in either group, or in peak response to thyrotrophin releasing hormone or in the increment at 20 minutes. One of the patients had a delayed response typical of a hypothalamic disorder, whereas none of the controls had such a response. Mean free thyroxine index levels for each group were similar. There was no difference in basal prolactin level, or in the increment or in the peak level in response to thyrotrophin releasing hormone between each group as a whole or when the males and females were analysed separately. Because of small subgroups, the data from the gonadotrophin releasing hormone test were difficult to analyse, but no clear differences or obvious abnormalities emerged. Water deprivation revealed no evidence of inability to concentrate urine in either group and hence no indication of impaired antidiuretic hormone function. The study supports previous findings of altered hypothalamic function in patients with Huntington's chorea but further suggests that serotoninergic rather than dopaminergic mechanisms may be altered.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6455503      PMCID: PMC490985          DOI: 10.1136/jnnp.44.5.414

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice.

Authors:  G M Everett; J W Borcherding
Journal:  Science       Date:  1970-05-15       Impact factor: 47.728

2.  Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase.

Authors:  G Bartholini; M Da Prada; A Pletscher
Journal:  J Pharm Pharmacol       Date:  1968-03       Impact factor: 3.765

3.  The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus.

Authors:  R Hall; B J Ormston; G M Besser; R J Cryer
Journal:  Lancet       Date:  1972-04-08       Impact factor: 79.321

4.  Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration.

Authors:  S Podolsky; N A Leopold
Journal:  J Clin Endocrinol Metab       Date:  1974-07       Impact factor: 5.958

5.  Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel.

Authors:  J Takahara; A Arimura; A V Schally
Journal:  Endocrinology       Date:  1974-08       Impact factor: 4.736

6.  Striatal amines, experimental tremor and the effect of harmaline in the monkey.

Authors:  L J Poirier; T L Sourkes; G Bouvier; R Boucher; S Carabin
Journal:  Brain       Date:  1966-03       Impact factor: 13.501

7.  Stimulation of human-growth-hormone secretion by L-dopa.

Authors:  A E Boyd; H E Lebovitz; J B Pfeiffer
Journal:  N Engl J Med       Date:  1970-12-24       Impact factor: 91.245

8.  Interrelationships in the regulation of TSH and prolactin secretion in man: effects of L-dopa, TRH and thyroid hormone in various combinations.

Authors:  S Refetoff; V S Fang; B Rapoport; H G Friesen
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

9.  Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.

Authors:  E G Spokes
Journal:  Brain       Date:  1980-03       Impact factor: 13.501

10.  Plasma growth hormone concentrations in Huntington's chorea.

Authors:  O T Phillipson; E D Bird
Journal:  Clin Sci Mol Med       Date:  1976-06
View more
  14 in total

1.  Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease.

Authors:  Takashi Kudo; Analyne Schroeder; Dawn H Loh; Dika Kuljis; Maria C Jordan; Kenneth P Roos; Christopher S Colwell
Journal:  Exp Neurol       Date:  2010-12-22       Impact factor: 5.330

2.  Insulin-induced hypoglycaemia does not abolish chorea.

Authors:  N P Quinn; A E Lang; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-10       Impact factor: 10.154

3.  Insulin-induced hypoglycaemia does not abolish chorea.

Authors:  N P Quinn; A E Lang; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

4.  Periodic alternating nystagmus in a case of hereditary ataxia and its treatment with baclofen.

Authors:  G T Plant
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-10       Impact factor: 10.154

5.  Loss of huntingtin-associated protein 1 impairs insulin secretion from pancreatic β-cells.

Authors:  Austin Cape; Xingxing Chen; Chuan-En Wang; Ashley O'Neill; Yung-Feng Lin; Jun He; Xing-Shun Xu; Hong Yi; He Li; Shihua Li; Xiao-Jiang Li
Journal:  Cell Mol Life Sci       Date:  2011-05-05       Impact factor: 9.261

6.  Autonomic nervous system function in Huntington's disease.

Authors:  J Andrich; T Schmitz; C Saft; T Postert; P Kraus; J T Epplen; H Przuntek; M W Agelink
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

7.  Regulation of L-type Ca2+ Channel Activity and Insulin Secretion by Huntingtin-associated Protein 1.

Authors:  Jing-Ying Pan; Shijin Yuan; Tao Yu; Cong-Lin Su; Xiao-Long Liu; Jun He; He Li
Journal:  J Biol Chem       Date:  2016-09-13       Impact factor: 5.157

8.  Sleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's disease.

Authors:  Dika Kuljis; Analyne M Schroeder; Takashi Kudo; Dawn H Loh; David L Willison; Christopher S Colwell
Journal:  Minerva Pneumol       Date:  2012-09

9.  Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.

Authors:  Mahmoud A Pouladi; Yuanyun Xie; Niels Henning Skotte; Dagmar E Ehrnhoefer; Rona K Graham; Jeong Eun Kim; Nagat Bissada; X William Yang; Paolo Paganetti; Robert M Friedlander; Blair R Leavitt; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2010-01-22       Impact factor: 6.150

10.  Neuroendocrine disturbances in Huntington's disease.

Authors:  Nadine Saleh; Stéphane Moutereau; Alexandra Durr; Pierre Krystkowiak; Jean-Philippe Azulay; Christine Tranchant; Emmanuel Broussolle; Françoise Morin; Anne-Catherine Bachoud-Lévi; Patrick Maison
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.